First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. - Wikidata - awgldk - TriplyDB

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.

http://www.wikidata.org/entity/Q38296268

about

Aptamers in Therapeutics Aptamers: A Feasible Technology in Cancer Immunotherapy Aptamer-nanoparticle complexes as powerful diagnostic and therapeutic tools.From selection hits to clinical leads: progress in aptamer discovery Aptamers in diagnostics and treatment of viral infections A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1 Structural basis for specific inhibition of Autotaxin by a DNA aptamer Modulation of the Coagulation Cascade Using Aptamers Functional display of platelet-binding VWF fragments on filamentous bacteriophage Techniques for molecular imaging probe design Progress in molecular imaging in endoscopy and endomicroscopy for cancer imaging.Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays.Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.Novel therapies in the pipeline: Directions of research into platelet inhibition Thrombotic microangiopathies: multimers, metalloprotease, and beyond.Targeting von Willebrand factor and platelet glycoprotein Ib receptor.Investigational drugs in thrombotic thrombocytopenic purpura.The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model Aptamers: from bench side research towards patented molecules with therapeutic applications.Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.The crystal structure of the active domain of Anopheles anti-platelet protein, a powerful anti-coagulant, in complex with an antibody.Triggers, targets and treatments for thrombosis.Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.Nucleic acid aptamers: clinical applications and promising new horizons Identification of a small molecule that modulates platelet glycoprotein Ib-von Willebrand factor interaction Anti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer.Development of universal antidotes to control aptamer activity.von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.Newer agents in antiplatelet therapy: a review.In situ Protein Detection for Companion Diagnostics.Aptamer-based therapeutics: new approaches to combat human viral diseases The chemical biology of aptamers.

P2860

Q26738413-B5975548-4226-4141-A563-FE689DC18FC9 Q26740303-E0216D06-A2DA-42B4-89CF-508E2833C481 Q26752263-4CEECA31-ADF7-425C-AA76-E415A306F45F Q26752799-EB2E156B-1196-4BC4-843C-5C2641456DDB Q27014527-A8B64045-10C9-4F94-B455-C38006F88416 Q27658166-5AD773E9-D29B-44A0-8833-202EC4C28FEC Q27704519-AD73F1AF-6D6B-409E-AA12-F065B446E64A Q28816936-A640701C-10BA-41C3-87C5-52A640017642 Q30353471-851D12B5-5BAC-4A26-8A80-1CEAD72885A5 Q30423734-9BB7C7FF-D703-4EC0-AB95-49D43399D51A Q30426514-AC1484F0-9DA2-4E71-AA2E-F33193B101B4 Q30448290-55CDF603-3C2C-447B-845B-ADFDF5F553F4 Q30498050-663B256B-024E-445D-B9E2-0D82BB331349 Q30498119-05FDCA90-4A5E-4CE6-A4A6-725068AC74E5 Q33353375-40F765C9-90F6-4D8F-BE38-9697B689AC44 Q33389435-DE0E5F1B-60C2-4F61-8290-BDFE0F84E2CD Q33392975-5F1AB0B6-5F24-44A8-AE13-CA18745F645A Q33395696-58571249-489F-40C7-964D-9A80CDB675A3 Q33405692-36CDF1E5-00CA-44E7-9389-49C221CBEE33 Q33419324-B4E8BF5F-18AA-4381-9212-ED6B6EADC56F Q33441990-DF3A3C38-929A-4484-99F8-FD7B9A2C2523 Q33512089-DA990264-502B-4063-9E0D-56176848705E Q33685876-1750F5D7-8C32-4FF4-B7F1-0B6D0A48A6B9 Q33718529-531433AD-ED39-4D72-AE44-E0044D68C35D Q33765444-61630D02-22BB-43EA-8E61-AF6ECC1C532F Q33901933-B119701F-51EC-4636-8768-7F5AB7ABAFDC Q34028112-36C7C7B2-40AA-4166-9F61-B064AE048E00 Q34122627-76459DD6-35BB-4DCD-B140-A6E802F14F8B Q34306827-BE64C139-9607-4EA5-A9E3-87F9D5C52122 Q34433842-E7BCBBAA-F3CA-4677-AD0C-79E4B4A5CE04 Q34666946-4190803A-8854-4429-AEDA-E0F1769DD285 Q35413768-75085279-1CC6-4118-B284-119153D6A4E9 Q35536246-ACEA5E1B-0306-4758-ADC6-311D447FAD0C Q35671956-939A8B15-BAE9-4FB2-9280-822FCE71F875 Q35750010-45F99289-E332-49A8-9350-31EDD8DE889D Q35757741-6DDE1809-54AD-44C0-9E69-21D147BB8883 Q36085620-CDB71BDA-CE5A-4BB3-A860-10DF1C5B843F Q37270405-5DF2C62F-B3F9-41D5-A0E6-DC0576123E01 Q37415958-76761724-7C69-4CDF-9485-99A0AE2C0F1F Q37423243-3A1E6222-A7CC-4A1D-ADB9-F603EE1A2724

P2860

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.

http://www.wikidata.org/entity/Q38296268

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

First-in-human evaluation of a ...... ARC1779 in healthy volunteers.

@en

type

label

First-in-human evaluation of a ...... ARC1779 in healthy volunteers.

@en

prefLabel

First-in-human evaluation of a ...... ARC1779 in healthy volunteers.

@en

P1433

Q38296268-67872E55-6CDF-4011-B5E3-61F4160D167B

P1476

Q38296268-DDD260EE-00A9-444A-BA9E-3E5228A38A54

P2093

Q38296268-27DAF180-774A-4519-B848-821E9DDCBBED

Q38296268-4D29A3BB-05D5-4062-9E37-3F1D71B77926

Q38296268-75A5EF61-6166-4B17-B0CE-823383FEE73D

Q38296268-96007BB8-0EB3-48DE-9E71-337C91DF7E41

Q38296268-9A009A8F-DC88-489A-8A05-068BDE00D3E2

Q38296268-9AD47F28-E9A5-4B55-BE9D-50F34A893795

Q38296268-A005E6D7-4941-4AC2-BAC1-6B1ED37E9809

Q38296268-B9136AFD-77C4-4070-A189-0BAC10EC3507

Q38296268-BA25FCBF-D969-4423-867C-764939494905

Q38296268-D9A2DB56-9A9E-4C0A-A727-0BF1D4F71884

P304

Q38296268-01290E74-2CAC-47C7-A18D-2C8E45986DDD

P31

Q38296268-6A5C7FCE-08AD-4512-9421-2E593EBE00E7

P356

Q38296268-108D27F6-51D3-4436-858A-76F9D7D3E718

P407

Q38296268-0A0AD3DF-E174-4260-A039-71FE59F3AD12

P433

Q38296268-DDFCE00E-4C7E-490C-8BBA-F93F64C407B9

P478

Q38296268-01F38CF9-4BBD-468E-8F38-B087390F6482

P577

Q38296268-918D31EE-67A1-44A8-8887-F56467CE8D1C

P698

Q38296268-99B1C25A-9DE6-41D2-92D2-BB17F82EECEE

P356

CIRCULATIONAHA.107.724864

P1433

P1476

First-in-human evaluation of a ...... ARC1779 in healthy volunteers.

@en

P2093

Christopher J Horvath

http://www.w3.org/2001/XMLSchema#string

H Nicholas Marsh

http://www.w3.org/2001/XMLSchema#string

James C Gilbert

http://www.w3.org/2001/XMLSchema#string

Judith M Healy

http://www.w3.org/2001/XMLSchema#string

Patricia G Merlino

http://www.w3.org/2001/XMLSchema#string

Renta M Hutabarat

http://www.w3.org/2001/XMLSchema#string

Robert G Schaub

http://www.w3.org/2001/XMLSchema#string

Sleiman Boufakhreddine

http://www.w3.org/2001/XMLSchema#string

Thomas V Holohan

http://www.w3.org/2001/XMLSchema#string

Tia DeFeo-Fraulini

http://www.w3.org/2001/XMLSchema#string

P304

2678-2686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.107.724864

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18025536

http://www.w3.org/2001/XMLSchema#string